Tuesday, February 3, 2026

Tanja Villumsen succeeds Thomas Rantzau as employee representative on the Board of Directors of Novo Nordisk A/S

At the Danish healthcare company Novo Nordisk A/S, there has been a change on the Board of Directors. Thomas Rantzau, who has served as an employee representative on the Board since 2018, has decided to pursue new professional opportunities outside the company. After a total of 22 years with Novo Nordisk, he is stepping down from his position on the Board.

With immediate effect, his former alternate, Tanja Villumsen, joins the Board of Directors of Novo Nordisk A/S. She takes on the role of employee representative and will represent the interests of employees at the highest level of corporate governance.

Novo Nordisk is one of the world’s leading healthcare companies and was founded in 1923. Headquartered in Denmark, the company is dedicated to driving change in the fight against serious chronic diseases, building on its strong heritage in diabetes care. Its activities focus on pioneering scientific breakthroughs, expanding access to medicines, and working to prevent and ultimately cure disease.

Today, Novo Nordisk employs approximately 78,500 people across 80 countries and markets its products in around 170 countries worldwide. The company’s B shares are listed on Nasdaq Copenhagen, while its ADRs are traded on the New York Stock Exchange. The change on the Board highlights the continued importance of employee representation within Novo Nordisk’s corporate leadership.